The Market Calm Before The Storm?... And Lionsgate’s Nasdaq Debut 5/14/24

Apple and Netflix both having strong weeks as the stocks trade near record highs. What’s next for the names and what could their rise mean for the rest of the markets? Plus long-struggling Gilead getting a boost today on early results of its experimental obesity pill. Can it effectively compete with the likes of Eli Lilly and Novo Nordisk? Fast Money Disclaimer

Tesla shareholders voting on CEO Elon Musk’s pay package. The billions that could come his way, and if the EV maker’s incorporation will stay in Delaware or head to the lone star state. Plus Media stocks in the red as the future of television and streaming continue to evolve. What the stock moves could be telling us about the media landscape. Fast Money Disclaimer

Another pause out of Powell, as the Federal Reserve leaves rates unchanged, noting some progress on inflation. What the central bank is forecasting for rate cuts this year. Plus The rate decision’s impact on financial stocks. Why one top bank analyst says it could be a boost for the group. Fast Money Disclaimer

Shares of Apple jumping to record highs just a day after falling flat on its new AI announcements. The turnaround for the tech titan, and what it means for the market. Plus The weight loss wars rage on… and we’re honing in on oral version of GLP-1’s. How one pharma stock is faring in the space, and how their results stack up against the competition. Fast Money Disclaimer

Apple upping the AI wars with their latest announcement: Apple Intelligence. How the new tech titan’s new push into AI will stack up, and how they’re incorporating ChatGPT. Plus European elections skewing to the right, all while investors here at home await a key Fed decision. How it all will impact markets. Fast Money Disclaimer

Rates surging after this morning’s stronger-than-expected jobs report. How the hot data is impacting the likelihood of a Fed rate cut. Plus Gamestop taking a big leg lower, as the company plans a big stock sale. What they could do with the money, and how Roaring Kitt’s livestream didn’t seem to help shares. Fast Money Disclaimer 

Veteran "Halftime" guest and investor Jim Lebenthal sat down with CNBC's Dominic Chu to discuss how the former nuclear engineer and U.S. Navy officer created a science-minded approach to fundamental analysis and value investing that has led to a decades-long career on Wall Street. Lebenthal goes into detail on how he uses different fundamental analytical tools, walking Pro subscribers through how he finds price-to-earnings growth ratios of stocks like Amazon and Nvidia. He also gives examples of how to incorporate tools from technical analysis to help augment his decision-making process, and fields stock-specific questions from Pro subscribers. CNBC Pro Talks features one-on-one interviews with Wall Street’s top investors, smartest traders and rising stars. CNBC’s Dominic Chu finds out what makes them tick, what makes them money, and how you can follow in their footsteps. CNBC Pro Talks is a monthly interview series that’s part of CNBC’s premium subscription service, CNBC Pro. To hear the full Pro Talk interview—including specific stock picks and investment strategies—listeners can subscribe to [cnbc.com/protalks].

Commodities rising across the board, as oil, metals, and agricultural prices all climb. But as those all head higher, rates continue to fall. What the moves could be saying about the market. Plus Eli Lilly’s Alzheimer’s treatment raising some eyebrows at the FDA. What regulators are flagging, and how it could impact the future of the drug. Fast Money Disclaimer

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed. Fast Money Disclaimer

The traders lay out the one chart telling the real market story. How the levels and price action in these areas could detail where stocks head next. Plus One telehealth company launching a weight loss drug tracker, as the surge in popularity causes shortages. How they’re tipping the scales in the obesity drug wars. Fast Money Disclaimer